Core Insights - The company is entering a pivotal year marked by significant progress in patient access, clinical development, and operational readiness [1] - The discussion will include forward-looking statements that are subject to risks and uncertainties [2] Company Developments - Recent collaboration with Zydus has been closed, which is expected to enhance operational capabilities for the company [3] - There is an expansion of France's reimbursed AAC program, particularly relevant for sarcomas, indicating a growing interest from physicians and patients [3] Leadership Engagement - The leadership team, including the Chief Medical Officer, Chief Medical Affairs Officer, and Chief Commercial Officer, will participate in a live Q&A session to address stakeholder inquiries [4]

Core Viewpoint - Bidafarma has invested in Hanshi Aitai, becoming one of its significant shareholders, and is inquiring about the innovative directions and achievements of Hanshi Aitai, as well as potential collaborations in technology and sales [1] Group 1: Company Overview - Hanshi Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. is an innovative biotech company focused on structural biology, translational medicine, and clinical development [1] - The company has established a product pipeline centered on self-innovated drugs targeting tumors and immune diseases [1] Group 2: Technological Innovations - Hanshi Aitai has developed a globally patented high-affinity, long half-life antibody screening platform [1] - The company has also created an innovative technology platform for tumor-targeted Geographical Positioning Small molecule-Antibody (GPSmAb) [1] Group 3: Shareholding and Future Collaborations - Bidafarma currently holds a 4.72% stake in Hanshi Aitai [1] - Any significant future collaborations will be disclosed in accordance with legal regulations [1]